AvenCell Therapeutics
AvenCell just dosed the first patient with a CRISPR-engineered allogeneic CAR-T that simultaneously targets CD19 and CD20 — with a built-in switchable receptor that lets you retarget the same cells post-infusion.
US-Based
Clinical-Stage
Cell Therapy
Oncology
Platform
Why Highlight AvenCell Now?
AvenCell just dosed the first patient in its Phase I QUADvance study with AVC-203 — the world’s first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T to enter clinical testing. Backed by $250M from Blackstone, a $112M Series B led by Novo Holdings, and a $40M AMED grant from Japan, this is one of the most well-capitalized allogeneic CAR-T programs in the world entering the clinic.
🔭 Company Snapshot
📋 Company Overview
AvenCell Therapeutics is engineering CAR-T cells that solve the three biggest problems in the field simultaneously: they’re off-the-shelf (allogeneic, from healthy donors), they hit two targets at once (CD19 and CD20, closing the antigen escape loophole), and they come with a built-in kill switch and retargeting capability via the proprietary RevCAR receptor system.
Created in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics, AvenCell merged GEMoaB’s switchable CAR-T platform with Intellia’s CRISPR/Cas9 allogeneic editing. The result is TruAllo — a manufacturing process that edits healthy donor T cells to evade both graft-versus-host disease and host rejection, while maintaining the fitness advantage of T cells that haven’t been battered by prior chemotherapy. Operations span Watertown, MA and Dresden, Germany.
🧬 Pipeline Overview
AVC-203 — Allo CD19/CD20 Dual-Target RevCAR-T in B-Cell Malignancies
CRISPR-engineered allogeneic CAR-T combining constitutive CD19/CD20 dual-targeting with RevCAR switchable receptor. First patient dosed April 2026 in QUADvance Phase I/II (NCT07284433). FDA IND and EMA CTA cleared. Supported by $40M AMED grant for Asia-Pacific development. Phase Ia dose escalation → Phase Ib expansion → Phase II pivotal in DLBCL.
AVC-201 — Allo CD123-Directed Switchable RevCAR-T in AML
Allogeneic switchable CAR-T targeting CD123 via separately infused targeting module (R-TM123). The RevCAR system allows T cells to be turned off within 4 hours by withholding the targeting module — critical for CD123, which is expressed on both leukemic blasts and normal hematopoietic stem cells. Phase 1 dosing ongoing in r/r AML (NCT05949125). Early safety and activity data described as promising.
Autoimmune Program — RevCAR-T for Autoimmune Diseases
Leveraging the switchable allogeneic platform for autoimmune indications — an area where controllability and off-the-shelf availability could be transformative. The RevCAR on/off mechanism is particularly suited to autoimmune applications where permanent B-cell depletion isn’t the goal.
⚔️ Competitive Landscape
| Company | Approach | Stage | Differentiator |
|---|---|---|---|
| AvenCell | CRISPR allo dual-target + RevCAR switch | Phase 1 | Only switchable + dual-target + allo in one product; post-infusion retargeting |
| Caribou Biosciences | CRISPR allo CAR-T (CAS12a, anti-CD19) | Phase 1 | CAS12a editing; CB-010 clinical data in r/r LBCL; single-target |
| CRISPR Therapeutics | CRISPR allo CAR-T (CTX110/112) | Phase 1 | First CRISPR allo CAR-T dosed; single-target; no switch mechanism |
| Novartis | Kymriah (autologous CD19 CAR-T) | Commercial | First-ever approved CAR-T; autologous benchmark; weeks to manufacture |
| Gilead/Kite | Yescarta (autologous CD19 CAR-T) | Commercial | Market leader in LBCL; $1.5B+ revenue; autologous manufacturing bottleneck |
Key insight: The allo CAR-T space is fiercely competitive, but every other program in the clinic is single-target and permanently on. AvenCell is the only company combining three features in one product: allogeneic manufacturing, dual-antigen targeting, and a switchable receptor that allows post-infusion control and target redirection. If TruAllo delivers persistence matching autologous therapies, AvenCell has the most flexible off-the-shelf platform in the field.
📊 Market Context
The global CAR-T cell therapy market reached ~$3.5B in 2024 and is projected to exceed $20B by 2030, but current autologous products remain bottlenecked by patient-specific manufacturing, weeks-long vein-to-vein times, and single-target antigen escape driving 30-60% relapse rates. B-cell malignancies account for ~270,000 new diagnoses annually across the US and Europe. An off-the-shelf, dual-target, controllable CAR-T that matches autologous persistence would fundamentally restructure the treatment algorithm — and the economics — of this market.
💡 Potential Impact
The unlock: CAR-T therapy works — response rates are spectacular — but the autologous model can’t scale. Manufacturing takes weeks, costs $400K+, and depends on T cells from patients already immunocompromised by prior treatment. If AvenCell’s allogeneic platform matches autologous durability while adding dual-targeting and on/off control, it transforms CAR-T from a last-resort specialty product into a broadly deployable, repeatable treatment option across oncology and autoimmune disease.
For investors: AvenCell is among the best-capitalized private cell therapy companies in the world ($362M+ deployed). The QUADvance first-patient dosing is the key de-risking milestone — initial safety and expansion data over the next 12-18 months will determine whether dual-target allo CAR-T can match the efficacy of Yescarta and Kymriah. The binary question: does TruAllo persistence hold? If yes, AvenCell is an acquisition target for any pharma with a cell therapy franchise.
For pharma BD: The RevCAR switchable architecture is the underappreciated asset. It means a single infusion of AvenCell’s cells could theoretically be redirected to new targets via different targeting modules — a platform play that extends far beyond lymphoma. Any company building a cell therapy franchise should be evaluating this technology before the QUADvance data readout shifts AvenCell’s negotiating leverage.
AvenCell Therapeutics
| Founded: | 2021 |
| Location: | Watertown, MA / Dresden, DE |
| Stage: | Clinical |
| Status: | Private |
| Funding: | $362M+ |
| Lead Investors: | Blackstone / Novo Holdings |
Company Leadership
Key Technology
RevCAR Switchable Platform — Universal receptor activated only when bound to a separately infused targeting module. Enables on/off control within 4 hours and future target redirection via different modules — without engineering new cells.
TruAllo CRISPR Engineering — Multi-gene CRISPR/Cas9 editing of healthy donor T cells to eliminate GvHD risk and host rejection, leveraging Intellia’s platform. Designed for improved persistence vs. first-gen allogeneic approaches.
The Biotech Voyager · Company profiles powered by HOUSTON intelligence
